Effect of dopamine agonist withdrawal after long-term therapy
in prolactinomas. 26. Colao A, Di Sarno A, Cappabianca P,
Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for
tumoral and nontumoral hyperprolactinemia. Long-term treatment with cabergoline, a new long-lasting ergoline
derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Cabergoline and cardiac valve disease in prolactinoma patients:
additional studies during long-term treatment are required.
34. Jones J, Bashir T, Olney J, Wheatley T. Cabergoline treatment for a
large macroprolactinoma throughout pregnancy. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
40. Laloi-Michelin M, Ciraru-Vigneron N, Meas T.
Cabergoline treatment of pregnant women with macroprolactinomas.
31. Konopka P, Raymond JP, Merceron RE, Seneze J.
Continuous administration of bromocriptine in the
prevention of neurological complications in pregnant women with prolactinomas.
19. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G.
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia
in men and women. |